sponsored
PatientsVille.com Logo

PatientsVille

Phenoxymethyl penicillin Medical Research Studies

Up-to-date List of Phenoxymethyl penicillin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Phenoxymethyl penicillin Medical Research Studies

Rank Status Study
1 Recruiting Improving Medication-taking After Liver Transplant
Conditions: Nonadherence;   Tacrolimus;   Pediatric Liver Transplant Recipients
Intervention: Behavioral: Telemetric
Outcome Measures: Change in Adherence;   Change in Incidence of rejection;   Liver Enzyme Levels;   Feasibility
2 Recruiting Remission From Stage D Heart Failure
Condition: NYHA Class IIIB/IV Patients Eligible for HeartMate II Implant Either as BTT or DT
Interventions: Device: HeartMate II;   Drug: Pharmacological Treatment
Outcome Measures: Proportion of subjects who experience LVAD removal and subsequent freedom from mechanical circulatory support or heart transplantation;   The proportion of evaluable subjects meeting explant criteria and subsequently explanted;   The time course of reverse remodeling on a left ventricular assist device;   The time course and sustainability of reverse remodeling following LVAD explantation;   Predictors of recovery and device removal;   Changes in maximal and sub maximal exercise capacity;   Changes in renal function and hepatic enzymes;   Changes in EF measured at 6000RPM.;   Changes in quality of life, as measured by the EuroQoL (EQ5D)
3 Unknown  Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Conditions: Heart Failure;   Dilated Cardiomyopathy
Intervention: Drug: clenbuterol
Outcome Measures: Percent of subjects who experience LVAD removal and subsequent freedom from mechanical circulatory support or heart transplantation for 1-year after explantation;   The proportion of evaluable subjects meeting explant criteria and subsequently explanted;   Safety and tolerability of clenbuterol;   To determine the time course of reverse remodeling on a left ventricular assist device during phase I (heart failure medications) and phase II (clenbuterol) of the HARPS protocol;   To determine the time course and sustainability of reverse remodeling following LVAD explantation;   To assess the biochemical, structural, cellular and molecular changes in the myocardium resulting from the HARPS protocol interventions;   To determine predictors of recovery of left ventricular function/remodeling and of LVAD removal;   To assess changes in body mass, lean muscle mass, muscle strength and maximal and submaximal exercise capacity;   To assess changes in renal function and Hepatic Enzymes;   To assess changes in quality of life, as measured by the EuroQoL (EQ5D) and Minnesota Living with Heart Failure Questionnaire (MLHFQ) questionnaires;   To assess changes in systemic inflammation, circulating progenitor cells and growth factors
4 Unknown  Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide
Condition: Diabetes
Intervention:
Outcome Measure: HbA1c
5 Unknown  Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Condition: Non-Alcoholic Fatty Liver Disease
Interventions: Drug: Fish Oil Supplementation;   Drug: Placebo Supplementation
Outcome Measures: 1. To evaluate whether young adults with obesity related NAFLD will normalize their elevated liver enzyme levels with supplements of fish oil (n-3 FA containing eicosapentanoic acid and decosahexaenoic acid).;   Attenuation of insulin resistance
6 Recruiting Effects of Obex in Overweight and Obese Patients
Conditions: Overweight;   Obesity
Intervention: Dietary Supplement: Obex
Outcome Measures: To evaluate the effect of Obex® on fasting glucose levels;   To determine the safety of serious supplement-related adverse events;   To evaluate the effect of Obex® on fasting insulin levels;   • To evaluate the effect of Obex® on insulin sensitivity by homeostasis model assessment-estimated insulin resistance (HOMA-IR), calculated from individual serum measures (fasting insulin x fasting glucose/22.5);   To evaluate the effect of Obex® on insulin sensitivity by quantitative insulin sensitivity check index, Bennett and Raynaud insulin sensitivity indexes;   • To evaluate the effect of Obex® on β-cell function by homeostatic model assessment-beta cell (HOMA-β), calculated from individual serum measures (20 x fasting insulin (µU/mL)/fasting glucose (mmol/L)-3.5);   • To evaluate the effect of Obex® on cholesterol, triglyceride and high density lipoprotein cholesterol levels (HDL-c);   To evaluate the effect of Obex® on Glycosylated Hemoglobin (HbA1c);   To evaluate the effect of Obex® on the body weight.;   • To evaluate the effect of Obex® on Body Mass Index (BMI) and Conicity Index (CI);   To evaluate the effect of Obex® on the waist and hip circumferences;   To evaluate the effect of Obex® on arterial blood pressures (BP);   • To evaluate the effect of Obex® on Hepatic Enzymes (Alanine aminotransferase, Aspartate aminotransferase, gamma-glutamyltransferase, Alkaline Phosphatase);   To evaluate the effect of Obex® on creatinine and uric acid concentrations;   To evaluate the effect of Obex® on haemoglobin and serum iron levels
7 Recruiting Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis
Condition: Non-alcoholic Steatohepatitis
Interventions: Drug: Atorvastatin;   Drug: L-Carnitine;   Drug: Placebo
Outcome Measures: improvement in liver stiffness;   improvement in liver enzyme levels;   Adverse drug events
8 Recruiting Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)
Condition: HIV-1 Infection
Intervention: Drug: Abacavir/Lamivudine/Dolutegravir
Outcome Measures: Percentage of patients with plasma HIV-1 RNA < 50 copies/mL at week 12;   Percentage of patients with Plasma HIV-1 RNA < 50 copies/ml at W24;   Percentage of patients with Plasma HIV-1 RNA < 50 copies/ml at W48;   Percentage of patients with undetectable plasma viral load (< 1 copies/ml or signal not detected) at W12;   Number of patients with undetectable plasma viral load (< 1 copies/ml or signal not detected) at W24;   Number of patients with undetectable plasma viral load (< 1 copies/ml or signal not detected) at W36;   Number of patients with undetectable plasma viral load (< 1 copies/ml or signal not detected) at W48;   Percentage of patients with adverse event of any Grade over 12 weeks;   Percentage of patients with adverse event of Grade 3 or 4 over 48 weeks;   CD4 and CD8 measurement;   Serum creatinine and GFR (MDRD) measurement;   Urinary albumine:creatinine ratio measurement;   Fasting lipids measurement;   Plasma concentration of NVP between Week 0 (W0) and Week 2 (W2);   Plasma concentration of dolutegravir between W0 and W12;   CD14 and usCRP measurement over 48 weeks;   Evaluation of patient's satisfaction with HIVTSQs and HIVTSQc questionnaires;   Plasma concentration of DTG on 24h at D0 and Week 2
9 Unknown  Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease
Condition: Meniere's Disease
Interventions: Drug: Acyclovir;   Drug: Placebo
Outcome Measures: Vertigo;   Hearing Loss;   Aural Fullness;   Tinnitus
10 Unknown  Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
Condition: Heterozigous Familial Hypercholesterolemia
Intervention: Drug: Statins and Ezetimibe
Outcome Measures: Evaluate if there is any correlation among the reduction of the plasma clearance of chylomicrons by the artificial chylomicrons technique and the presence of sub-clinical atherosclerosis;   Evaluate if ezetimibe/simvastatin enhances the effects of simvastatin alone in the removal of chylomicrons in patients with HF.
11 Recruiting Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
Conditions: Liver Disease;   Steatohepatitis;   HIV
Intervention:
Outcome Measures: Presence of hepatic fibrosis on liver biopsy as measured histologically by stage;   Liver biopsy evidence of hepatic steatosis as measured by degree (0 to 4), character and location;   Liver biopsy evidence of hepatic inflammation by type and severity;   Correlation between histopathologic findings on liver biopsy and clinical, laboratory and radiologic parameters
12 Not yet recruiting Effect of Exercise on Hepatic Fat in Overweight Children
Conditions: Non-alcoholic Fatty Liver Disease;   Obesity;   Metabolic Syndrome
Intervention: Other: Multidisciplinary intervention program
Outcome Measures: changes in hepatic fat;   Changes in Insulin sensitivity;   Changes in serum lipid profile;   Changes in liver enzymes;   Changes in dietary habits;   Changes in physical activity;   Changes in body composition;   Changes in other cardiometabolic risk factors
13 Recruiting Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
Conditions: Non Alcoholic Fatty Liver Disease;   Steatohepatitis;   Hypertriglyceridemia;   Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions: Dietary Supplement: Lovaza;   Other: Omega diet
Outcome Measure: reduction in hepatic fat fraction
14 Recruiting Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
Conditions: Adult Solid Neoplasm;   Hepatic Complication;   Renal Failure
Interventions: Drug: Dabrafenib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
Outcome Measures: Incidence of toxicities graded according to NCI CTCAE v4.0;   MTD of dabrafenib, defined as the highest dose level that is estimated to induce a dose-limiting toxicity (DLT) rate less than 33.3% by the two-way isotonic regression, graded according to NCI CTCAE v4.0;   Incidence of adverse events graded according to NCI CTCAE v4.0;   Best response, defined as the best objective status recorded from the start of treatment until disease progression/recurrence, measured by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria;   Time until any treatment-related toxicity;   Time until treatment related grade 3+ toxicity;   Time until hematologic nadirs (white blood cells [WBC], ANC, platelets);   Time to progression;   Time to treatment failure
15 Recruiting Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Conditions: Amatoxin Poisoning;   Amanita Poisoning;   Mushroom Poisoning;   Liver Failure
Intervention: Drug: Legalon SIL (Silibinin)
Outcome Measures: prevention of severe morbidity (liver transplantation) and death;   Improvement in presenting abnormalities as evaluated by time to normality for hepatic and renal function tests (AST, ALT, bilirubin, PT/INR, creatinine).;   cutaneous reactions;   sodium;   hemoglobin
16 Recruiting Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)
Condition: Hepatic Transplantation
Intervention: Other: Tacrolimus pharmacokinetics
Outcome Measures: Exposure to tacrolimus after the first administration, using tacrolimus area under curve (AUC) between 0 and 12 hours, weighted by the dose administered.;   Pharmacokinetics after the first administration and after 7 days of treatment;   Clinical follow-up during the 3 months post transplantation
17 Recruiting Fatty Acids, Genes and Microbiota in Fatty Liver
Conditions: Nonalcoholic Fatty Liver Disease;   Steatosis;   Nonalcoholic Steatohepatitis
Intervention:
Outcome Measures: Hepatic fatty acid composition in total lipids in liver biopsy;   Hepatic  gene expression;   Intestinal microbiota composition;   Lipid peroxides in the liver;   Hepatic  liver antioxidant power;   Hepatic  microRNA expression in the liver;   Intestinal microbiota - specific organisms and groups;   Intestinal microbiome on a genetic level;   Short-chain fatty acids in stool;   Plasma endotoxin
18 Recruiting Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV
Condition: Steatohepatitis
Intervention:
Outcome Measures: What is the spectrum of NAFLD in HIV;   How does the spectrum compare in those that are on a PI compare to those that are not.;   What are the independent predictive factors associated with hepatic steatosis and NASH?
19 Unknown  Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis
Condition: Wilson's Disease
Intervention: Genetic: allogeneic mesenchymal stem cell transplantation
Outcome Measure: differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies
20 Recruiting Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery
Condition: Hepatic Complications
Interventions: Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: sirolimus;   Procedure: quality-of-life assessment
Outcome Measure: Percentage of patients who are able to complete therapy

These studies may lead to new treatments and are adding insight into Phenoxymethyl penicillin etiology and treatment.

A major focus of Phenoxymethyl penicillin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Phenoxymethyl penicillin